Drugs / HS-10382
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06530810 | Jul 2024 → May 2026 overdue | leukemia, myeloid, accelerated-phase | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05367700 | Apr 2022 → Dec 2024 overdue | leukemia, myeloid, accelerated-phase | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10382 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06530810 ↗ |
| Action | Inhibit | “HS-10382 locks BCR-ABL1 into an inactive conformation.” NCT05367700 ↗ |
| Modality | Small molecule | “HS-10382 is a small molecular, oral potent, allosteric inhibitor.” NCT05367700 ↗ |
| Route | Oral | “HS-10382 is administered orally once daily.” NCT05367700 ↗ |